HubertChih-HsinChenMD

Summary

• •    C-level officer in the biotech/pharmaceutical industry, with 12 years of executive track record in both public and private companies and pivotal roles in initial/follow-on public offerings.
  •    Research & development experience across multiple therapeutic areas, with 10 additional years of basic research and teaching record in academia.
  •    Skilled in communicating with diverse audiences, including scientific and medical communities, board members, investors and analysts.
  •    Successfully designed and executed the clinical, nonclinical, and regulatory strategy for Bonsity® (PF708), a teriparatide injectable for the treatment of high-risk osteoporosis, leading to NDA approval in 2019.
  •    Experienced in negotiating with multiple regulatory agencies (US FDA, EMA, Japan’s PMDA, Health Canada), with a passion for translating scientific breakthroughs and proposing accelerated development programs.